Cannabis News Box

FDA presents Congress with eagerly anticipated CBD regulatory framework

FDA presents Congress with eagerly anticipated CBD regulatory framework

Bethan Rose Jenkins, Cannabis News Writer/Editorial

March 16, 2020

A press release was issued to the general public by the U.S. Food and Drug Administration (FDA) on Thursday, March 5. Included in the release was a CBD regulatory update addressed to Congress. The update has been long-awaited by everyone involved in the budding market, which is estimated to reach $2...

WHO: CBD should not be a scheduled under the Controlled Substances Act, carries no addiction risks

WHO: CBD should not be a scheduled under the Controlled Substances Act, carries no addiction risks

Sara Tiradossi

December 14, 2017

The World Health Organization has declared that cannabidiol (CBD) should not be a scheduled drug. The WHO Expert Committee on Drug Dependence released findings and scheduling recommendations on Wednesday for more than a dozen substances, and plans to undertake a fuller review of CBD in 2018. After...

WHO committee to examine CBD on international level

WHO committee to examine CBD on international level

Sara Tiradossi

September 22, 2017

The U.S. Food and Drug Administration has been collecting public input on CBD (cannabidiol) to find out how cannabis and its compound are regulated, as the World Health Organization is working to examine international regulations of the compound. To discuss the properties of CBD on a closer level,...

Sessions further impedes cannabis research

Sessions further impedes cannabis research

Logan Lowrey-Rasmussen

August 21, 2017

An anonymous senior Drug Enforcement Agency (DEA) official claimed Attorney General Jeff Sessions had effectively blocked an Obama Administration initiative to expand the number of cannabis suppliers for scientific research. Sessions or the Department of Justice had not released an official statement, but did not respond or take action on two dozen requests to grow cannabis for research. The Controlled Substances Act lists cannabis as a Schedule I drug, classifying it as more dangerous than cocaine. The Schedule I status of cannabis means the government does not recognize any legitimate medical use for the plant, which makes attaining the plant for research more difficult. Cannabis researchers who wish to conduct federal studies need a license from the DEA, approval from the U.S. Food and Drug Administration (FDA) and access to the single authorized source of legal cannabis from the University of Mississippi. Researchers had often complained about the low quality of cannabis the university produced. Late in the Obama administration, the DEA relaxed the constraints on cannabis production for research purposes and allowed other groups to apply for authorization to grow. In early August, the DEA released productio...

U.S. Food and Drug Administration